Ultragenyx Pharmaceutical Inc. (LON:0LIF)

Ultragenyx Pharmaceutical Statistics

Total Valuation

LON:0LIF has a market cap or net worth of GBP 1.69 billion. The enterprise value is 2.00 billion.

Market Cap	1.69B
Enterprise Value	2.00B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	96.30M
Shares Outstanding	n/a
Shares Change (YoY)	+12.26%
Shares Change (QoQ)	+1.33%
Owned by Insiders (%)	3.49%
Owned by Institutions (%)	97.69%
Float	92.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.59
PB Ratio	140.21
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.63
EV / Sales	4.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.94

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 53.41.

Current Ratio	1.89
Quick Ratio	1.59
Debt / Equity	53.41
Debt / EBITDA	n/a
Debt / FCF	-1.91
Interest Coverage	-9.37

Financial Efficiency

Return on equity (ROE) is -313.43% and return on invested capital (ROIC) is -31.69%.

Return on Equity (ROE)	-313.43%
Return on Assets (ROA)	-24.92%
Return on Invested Capital (ROIC)	-31.69%
Return on Capital Employed (ROCE)	-63.97%
Weighted Average Cost of Capital (WACC)	5.16%
Revenue Per Employee	362,540
Profits Per Employee	-333,352
Employee Count	1,294
Asset Turnover	0.46
Inventory Turnover	16.63

Taxes

In the past 12 months, LON:0LIF has paid 2.31 million in taxes.

Income Tax	2.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.94% in the last 52 weeks. The beta is 0.15, so LON:0LIF's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-45.94%
50-Day Moving Average	27.71
200-Day Moving Average	31.42
Relative Strength Index (RSI)	38.84
Average Volume (20 Days)	1,472

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.66

Income Statement

In the last 12 months, LON:0LIF had revenue of GBP 469.13 million and -431.36 million in losses. Loss per share was -4.42.

Revenue	469.13M
Gross Profit	-121.87M
Operating Income	-404.70M
Pretax Income	-429.04M
Net Income	-431.36M
EBITDA	-378.44M
EBIT	-404.70M
Loss Per Share	-4.42

Balance Sheet

The company has 316.36 million in cash and 642.10 million in debt, with a net cash position of -309.33 million.

Cash & Cash Equivalents	316.36M
Total Debt	642.10M
Net Cash	-309.33M
Net Cash Per Share	n/a
Equity (Book Value)	12.02M
Book Value Per Share	0.07
Working Capital	225.55M

Cash Flow

In the last 12 months, operating cash flow was -331.55 million and capital expenditures -4.25 million, giving a free cash flow of -335.81 million.

Operating Cash Flow	-331.55M
Capital Expenditures	-4.25M
Free Cash Flow	-335.81M
FCF Per Share	n/a

Margins

Gross margin is -25.98%, with operating and profit margins of -86.27% and -91.95%.

Gross Margin	-25.98%
Operating Margin	-86.27%
Pretax Margin	-91.46%
Profit Margin	-91.95%
EBITDA Margin	-80.67%
EBIT Margin	-86.27%
FCF Margin	n/a

Dividends & Yields

LON:0LIF does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.26%
Shareholder Yield	-12.26%
Earnings Yield	-25.59%
FCF Yield	-19.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0LIF has an Altman Z-Score of -3.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.98
Piotroski F-Score	4